Dopamine enhances glutamate-induced excitation of rat striatal neurons by cooperative activation of D1 and D2 class receptors

doi:10.1016/S0304-3940(97)13443-7

Neuroscience Letters

Volume 224, Issue 1, 7 March 1997, Pages 61-65

https://doi.org/10.1016/S0304-3940(97)13443-7 Get rights and content

Abstract

Although dopamine (DA) usually inhibits firing of rat striatal neurons in vivo, iontophoresis of DA with low ejection currents can also potentiate glutamate-evoked activity. We used extracellular single cell recording to examine the DA receptor subtypes involved in such potentiation. At low iontophoretic currents (1–8 nA), both the DA D1 class receptor agonist SKF 38393 and the DA D2 class receptor agonist quinpirole mimicked the ability of DA to facilitate glutamate-induced activity. Acute depletion of DA abolished the excitatory modulation produced by either D1 or D2 agonists but not by DA. Co-administration of SKF 38393 and quinpirole restored the facilitation of glutamate effects in DA-depleted rats. Stimulation of both D1 and D2 class receptors appears to be required for DA to enhance glutamate-induced firing of striatal neurons.

Section snippets

Acknowledgements

This research was supported by USPHS Grants DA-04093 and MH-40832 to F.J.W. who is also a recipient of a National Institute on Drug Abuse Research Scientist Development Award (DA 00207).

References (23)

P. Calabresi et al.
Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: evidence for D1 receptor involvement
Neuroscience
(1987)
L.A. Chiodo et al.
Interactions between dopamine and amino acid-induced excitation and inhibition in the striatum
Brain Res.
(1986)
D.J. Surmeier et al.
Modulation of calcium currents by a D₁ dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons
Neuron
(1995)
N. Uchimura et al.
Hyperpolarizing and depolarizing actions of dopamine via D-1 and D-2 receptors on nucleus accumbens neurons
Brain Res.
(1986)
F.J. White et al.
Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
Pharmacol. Biochem. Behav.
(1988)
Berger, T.W., Nisenbaum, E.S., Stricker, E.M. and Zigmond, M.J., Evidence for two functionally distinct subpopulations...
A.M. Bertorello et al.
Inhibition by dopamine of (Na⁺+K⁺) ATPase activity in neostriatal neurons through D₁ and D₂ dopamine receptor synergism
Nature
(1990)
P. Calabresi et al.
Vulnerability of medium spiny striatal neurons to glutamate: Role of Na⁺/K⁺ ATPase
Eur. J. Neurosci.
(1995)
P. Calabresi et al.
Long-term synaptic depression in the striatum: physiological and pharmacological characterization
J. Neurosci.
(1992)
C. Cepeda et al.
Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated
Proc. Natl. Acad. Sci. USA
(1993)

J.A. Gingrich et al.

Recent advances in the molecular biology of dopamine receptors

Annu. Rev. Neurosci.

(1993)

Cited by (89)

Amphetamines abuse and depression: Focus on TRPC channels
2023, Experimental Neurology
Amphetamines, such as amphetamine (AMPH), methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA), are the psychotropic substances widely abused in the world. Amphetamines abuse can damage dopaminergic and serotonin neurons and cause neuroinflammation and neurotoxicity. Neuropsychiatric disorders induced by amphetamines abuse include depression, anxiety, auditory hallucinations, mania, and cognitive disorders, of which depression has a higher incidence. Transient receptor potential (TRP) channels can regulate the inflow and outflow of Ca²⁺. In TRP family, transient receptor potential canonical (TRPC) channels are closely associated with the development of some neurological diseases, such as Parkinson's disease and Alzheimer's disease. However, the correlation between TRPC channels and depression and the specific mechanism of TRPC channels in depression still haven't been fully clarified. This review elaborates the pathophysiological mechanisms of depression induced by amphetamines abuse, the functions of TRPC channels in the nervous system, and the possible correlation between TRPC channels and depression induced by amphetamines abuse, which would provide the theoretical basis for the development of the novel and effective therapeutic drugs for amphetamines abuse-induced depression.
Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies
2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry
In people with schizophrenia, cognitive abilities – including memory – are strongly associated with functional outcome. Long-term potentiation (LTP) is a form of neuroplasticity that is believed to be the physiological basis for memory. It has been postulated that antipsychotic medication can impair long-term potentiation and cognition by altering dopaminergic transmission. Thus, a systematic review was performed in order to assess the relationship between antipsychotics and D2 antagonists on long-term potentiation.
The majority of studies on LTP and antipsychotics have found that acute administration of antipsychotics was associated with impairments in LTP in wild-type animals. In contrast, chronic administration and acute antipsychotics in animal models of schizophrenia were not. Typical and atypical antipsychotics and other D2 antagonists behaved similarly, with the exception of clozapine and olanzapine. Clozapine caused potentiation independent of tetanization, while olanzapine facilitated tetanus-induced potentiation.
These studies are limited in their ability to model the effects of antipsychotics in patients with schizophrenia as they were largely performed in wild-type animals as opposed to humans with schizophrenia, and assessed after acute rather than chronic treatment. Further studies using patients with schizophrenia receiving chronic antipsychotic treatment are needed to better understand the effects of these medications in this population.
Opioid self-administration results in cell-type specific adaptations of striatal medium spiny neurons
2013, Behavioural Brain Research
Medium-sized spiny neurons (MSNs), the predominant neuronal population of the striatum, are an integral component of the many cortical and limbic pathways associated with reward-related behaviors. A differential role of the D1 receptor-enriched (D1) MSNs of the striatonigral direct pathway, as compared with the D2 receptor-enriched (D2) MSNs of the striatopallidal indirect pathway, in mediating the addictive behaviors associated with cocaine is beginning to emerge. However, whether opioids, well-known analgesics with euphoric properties, similarly induce dissociable signaling adaptations in these neurons remains unclear. Transgenic mice expressing green fluorescent protein (GFP)-labeled D1 or D2 neurons were implanted with intravenous jugular catheters. Mice learned to self-administer 0.1 mg/kg/infusion of the opioid remifentanil during 2 h sessions over 13 contiguous days. Thereafter, the electrophysiological properties of D1- and D2-MSNs in the shell region of the nucleus accumbens (NAc) were assessed. We found that prior opioid exposure did not alter the basic membrane properties nor the kinetics or amplitude of miniature excitatory postsynaptic currents (mEPSCs). However, when challenged with the mu opioid receptor (μOR) agonist DAMGO, the characteristic inhibitory profile of this receptor was altered. DAMGO inhibited the frequency of mEPSCs in D1-MSNs from control mice receiving saline and in D2-MSNs from mice exposed to remifentanil or saline, but this inhibitory profile was reduced in D1-MSNs from mice receiving remifentanil. Remifentanil exposure also altered the probability of glutamate release onto D1-, but not D2-MSNs. Together these results suggest a D1-pathway specific effect associated with the acquisition of opioid-seeking behaviors.
Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: A saccadic eye movement study
2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
Interestingly, a similar non-monotonic relationship between dopamine dose and neural response has been observed in various brain areas. In these studies, a non-monotonic (inverted-U shaped) function was reported for dopamine levels and neural response in the cortex (Goldman-Rakic et al., 2000) and striatum (Hu and Wang, 1988; Hu and White, 1997; Nicola et al., 2000; Nisenbaum et al., 1988; Shen et al., 1992). This Gaussian model analysis was limited to antisaccade errors because differences for the other measurements (e.g. Stroop task), if they existed, were small and Gaussian functions were no better than linear functions.
Schizophrenic patients are heterogeneous with respect to voluntary eye movement performance, with some showing impairment (e.g., high antisaccade error rates) and others having intact performance. To investigate how this heterogeneity may correlate with different cognitive outcomes after treatment, we used a prosaccade and antisaccade task to investigate the effects of haloperidol in schizophrenic subjects at three time points: baseline (before medication), 3–5 days post-medication, and 12–14 days post-medication. We also investigated changes on the Stroop Task and the Positive and Negative Syndrome Scale (PANSS) in these same subjects. Results were compared to matched controls. When considered as a single patient group, haloperidol had no effects across sessions on reflexive and voluntary saccadic eye movements of schizophrenic patients. In contrast, the performance of the Control group improved slightly but significantly across sessions on the voluntary eye movement task. When each subject was considered separately, interestingly, for schizophrenic patients change in voluntary eye movement performance across sessions depended on the baseline performance in a non-monotonic manner. That is, there was maximal worsening of voluntary eye movement performance at an intermediate level of baseline performance and the worsening decreased on either side of this intermediate baseline level. When patients were divided into categorical subgroups (nonimpaired and impaired), consistent with the non-monotonic relationship, haloperidol worsened voluntary eye movement performance in the nonimpaired patients and improved performance in the impaired patients. These results were only partially reflected in the Stroop Test. Both patient subgroups showed clinically significant improvement over time as measured by the PANSS. These findings suggest that haloperidol has different effects on cognitive performance in impaired and nonimpaired schizophrenic patients that are not evident in clinical ratings based on the PANSS. Given that good cognitive function is important for long-term prognosis and that there is heterogeneity in schizophrenia, these findings are critical for optimal evaluation and treatment of schizophrenic patients.
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
2011, Experimental Neurology
Citation Excerpt :
In support of our effects, glutamate antagonism failed to reduce D1R-induced locomotor activity and striatal preprotachykinin mRNA expression in parkinsonian rat pups (Campbell et al., 2006). Taken as a whole, it is possible that stimulation of both DA receptor subtypes is necessary to augment striatal glutamate, as seen in vitro where stimulation of both D1R and D2R were required to enhance glutamate-induced firing of striatal neurons (Hu & White, 1997), in vivo where separate administration of D1R and D2R agonists did not affect striatal glutamate in intact animals (Yamamoto & Davy, 1992), and in vivo with apomorphine in intact rats (Porras & Mora, 1995) and l-DOPA in DA-depleted rats (current study; Robelet et al., 2004). Future work should investigate the effects of D2R agonist treatment on extracellular glutamate levels within the DA-depleted striatum, both alone and in conjunction with D1R agonism, to validate this hypothesis.
Serotonin 1A receptor (5-HT_1AR) agonists reduce both l-DOPA- and D1 receptor (D1R) agonist-mediated dyskinesia, but their anti-dyskinetic mechanism of action is not fully understood. Given that 5-HT_1AR stimulation reduces glutamatergic neurotransmission in the dopamine-depleted striatum, 5-HT_1AR agonists may diminish dyskinesia in part through modulation of pro-dyskinetic striatal glutamate levels. To test this, rats with unilateral medial forebrain bundle dopamine or sham lesions were primed with l-DOPA (12 mg/kg + benserazide, 15 mg/kg, sc) or the D1R agonist SKF81297 (0.8 mg/kg, sc) until abnormal involuntary movements (AIMs) stabilized. On subsequent test days, rats were treated with vehicle or the 5-HT_1AR agonist ± 8-OH-DPAT (1.0 mg/kg, sc), followed by l-DOPA or SKF81297, or intrastriatal ± 8-OH-DPAT (7.5 or 15 mM), followed by l-DOPA. In some cases, the 5-HT_1AR antagonist WAY100635 was employed to determine receptor-specific effects. In vivo microdialysis was used to collect striatal samples for analysis of extracellular glutamate levels during AIMs assessment. Systemic and striatal ± 8-OH-DPAT attenuated l-DOPA-induced dyskinesia and striatal glutamate efflux while WAY100635 reversed ± 8-OH-DPAT's effects. Interestingly, systemic ± 8-OH-DPAT diminished D1R-mediated AIMs without affecting glutamate. These findings indicate a novel anti-dyskinetic mechanism of action for 5-HT_1AR agonists with implications for the improved treatment of Parkinson's disease.
Mean-field modeling of the basal ganglia-thalamocortical system. I. Firing rates in healthy and parkinsonian states
2009, Journal of Theoretical Biology
Citation Excerpt :
However, observations on these effects are complicated and sometimes paradoxical. For instance, dopamine may facilitate glutamate-induced activity at low concentrations, but be inhibitory at higher concentrations (Hu and White, 1997). Joint activation of D1 and D2 receptors may have a supra-additive effect on striatal neurons, and upregulation of both receptor types after dopamine depletion may influence corticostriatal transmission (Hu et al., 1990).
Parkinsonism leads to various electrophysiological changes in the basal ganglia-thalamocortical system (BGTCS), often including elevated discharge rates of the subthalamic nucleus (STN) and the output nuclei, and reduced activity of the globus pallidus external (GPe) segment. These rate changes have been explained qualitatively in terms of the direct/indirect pathway model, involving projections of distinct striatal populations to the output nuclei and GPe. Although these populations partly overlap, evidence suggests dopamine depletion differentially affects cortico-striato-pallidal connection strengths to the two pallidal segments. Dopamine loss may also decrease the striatal signal-to-noise ratio, reducing both corticostriatal coupling and striatal firing thresholds. Additionally, nigrostriatal degeneration may cause secondary changes including weakened lateral inhibition in the GPe, and mesocortical dopamine loss may decrease intracortical excitation and especially inhibition. Here a mean-field model of the BGTCS is presented with structure and parameter estimates closely based on physiology and anatomy. Changes in model rates due to the possible effects of dopamine loss listed above are compared with experiment. Our results suggest that a stronger indirect pathway, possibly combined with a weakened direct pathway, is compatible with empirical evidence. However, altered corticostriatal connection strengths are probably not solely responsible for substantially increased STN activity often found. A lower STN firing threshold, weaker intracortical inhibition, and stronger striato-GPe inhibition help explain the relatively large increase in STN rate. Reduced GPe–GPe inhibition and a lower GPe firing threshold can account for the comparatively small decrease in GPe rate frequently observed. Changes in cortex, GPe, and STN help normalize the cortical rate, also in accord with experiments. The model integrates the basal ganglia into a unified framework along with an existing thalamocortical model that already accounts for a wide range of electrophysiological phenomena. A companion paper discusses the dynamics and oscillations of this combined system.

View all citing articles on Scopus

View full text

Dopamine enhances glutamate-induced excitation of rat striatal neurons by cooperative activation of D1 and D2 class receptors

Abstract

Section snippets

Acknowledgements

Neuroscience

Brain Res.

Neuron

Brain Res.

Pharmacol. Biochem. Behav.

Inhibition by dopamine of (Na++K+) ATPase activity in neostriatal neurons through D1 and D2 dopamine receptor synergism

Nature

Vulnerability of medium spiny striatal neurons to glutamate: Role of Na+/K+ ATPase

Eur. J. Neurosci.

Long-term synaptic depression in the striatum: physiological and pharmacological characterization

J. Neurosci.

Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated

Proc. Natl. Acad. Sci. USA

Recent advances in the molecular biology of dopamine receptors

Annu. Rev. Neurosci.

Inhibition by dopamine of (Na⁺+K⁺) ATPase activity in neostriatal neurons through D₁ and D₂ dopamine receptor synergism

Vulnerability of medium spiny striatal neurons to glutamate: Role of Na⁺/K⁺ ATPase